利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

14 条记录 (耗时 0.017 秒)

    In vitro activation of cytotoxic T cells
    2.
    发明授权
    In vitro activation of cytotoxic T cells 失效
    细胞毒T细胞的体外活化

    公开(公告)号：US6001365A

    公开(公告)日：1999-12-14

    申请号：US103486

    申请日：1998-06-24

    申请人： Per A. Peterson ,  Michael Jackson ,  Pierre Langlade-Demoyen

    发明人： Per A. Peterson ,  Michael Jackson ,  Pierre Langlade-Demoyen

    IPC分类号： A61K38/17 ,  A61P31/00 ,  A61P37/02 ,  A61K39/385 ,  A61K38/02 ,  C12N5/06

    CPC分类号： A61K38/1774 ,  A61K2039/5154 ,  A61K2039/5156

    摘要： The present invention relates to a rational, elegant means of producing, loading and using Class I molecules to specifically activate CD8 cells in vitro, and their therapeutic applications in the treatment of a variety of conditions, including cancer, tumors or neoplasias, as well as viral, retroviral, autoimmune, and autoimmune-type diseases. The present invention also relates to vectors, cell lines, recombinant DNA molecules encoding human .beta.2 microglobulin or Class I MHC molecules in soluble and insoluble form, and methods of producing same.

    摘要翻译： 本发明涉及生产，加载和使用I类分子以体外特异性激活CD8细胞的合理，优雅的手段，以及它们在治疗各种病症（包括癌症，肿瘤或肿瘤）中的治疗应用，以及 病毒，逆转录病毒，自身免疫和自身免疫性疾病。 本发明还涉及可溶性和不溶形式的编码人β2微球蛋白或I类MHC分子的载体，细胞系，重组DNA分子及其生产方法。

    Hybrid or chimeric polynucleotides, proteins, and compositions comprising hepatitis B virus sequences
    3.
    发明申请
    Hybrid or chimeric polynucleotides, proteins, and compositions comprising hepatitis B virus sequences 审中-公开
    杂种或嵌合多核苷酸，蛋白质和包含乙型肝炎病毒序列的组合物

    公开(公告)号：US20080107693A1

    公开(公告)日：2008-05-08

    申请号：US12004024

    申请日：2007-12-20

    申请人： Huseyin Firat ,  Francois Lemonnier ,  Pierre Langlade-demoyen ,  Marie-Louise Michel ,  Andreas Suhrbier

    发明人： Huseyin Firat ,  Francois Lemonnier ,  Pierre Langlade-demoyen ,  Marie-Louise Michel ,  Andreas Suhrbier

    IPC分类号： A61K39/00 ,  C07H21/04 ,  A61K31/7088 ,  A61P37/04 ,  A61P35/00 ,  C12N15/63

    CPC分类号： C07K14/005 ,  A61K39/0011 ,  A61K39/12 ,  A61K39/292 ,  A61K48/00 ,  A61K2039/5258 ,  A61K2039/57 ,  C07K2319/00 ,  C07K2319/40 ,  C12N2730/10122 ,  C12N2730/10134

    摘要： H-2 class I negative, HLA-A2.1 transgenic HHD mice were used for a comparative evaluation of the immunogenicity of HLA-A2.1 restricted human tumor-associated CTL epitopes. A hierarchy was established among these epitopic peptides injected into mice in IFA which correlates globally with their capacity to bind and stabilize HLA-A2.1 molecules. Co-injection of a helper peptide enhanced most CTL responses. In contrast, classical HLA class I transgenic mice which still express their own class I molecules did not, in most cases, develop H.A.-A2.1-restricted CTL responses under the same experimental conditions. Different monoepitopic immunization strategies of acceptable clinical usage were compared in HHD mice. Recombinant Ty-virus-like particles, or DNA encoding epitopes fused to the hepatitis B virus middle envelope protein gave the best results. Using this latter approach and a melanoma-based polyepitope construct, CTL responses against five distinct epitopes could be elicited simultaneously in a single animal. Thus, HHD mice provide a versatile animal model for preclinical evaluation of peptide-based cancer immunotherapy.

    摘要翻译： 使用H-2级I阴性，HLA-A2.1转基因HHD小鼠进行HLA-A2.1限制性人肿瘤相关CTL表位的免疫原性的比较评估。 在IFA中注射到小鼠中的这些表位肽之间建立了等级关系，其全局与其结合和稳定HLA-A2.1分子的能力相关。 辅助肽的共注射增强了大多数CTL应答。 相比之下，仍然表达自己的I类分子的经典HLA I类转基因小鼠在大多数情况下并不在相同的实验条件下产生H.A.-A2.1限制性CTL应答。 在HHD小鼠中比较了可接受的临床应用的不同单表位免疫策略。 重组的Ty病毒样颗粒或编码与乙型肝炎病毒中膜包膜蛋白融合的表位的DNA得到最好的结果。 使用后一种方法和基于黑素瘤的多表位构建体，可以在单个动物中同时诱导针对五种不同表位的CTL应答。 因此，HHD小鼠为基于肽的癌症免疫治疗的临床前评估提供了通用的动物模型。